The recent introduction of flexible multiplex infectious disease testing for respiratory pathogens is allowing laboratorians the ability to better adapt the testing they can offer to the needs of their providers and patients. Bert Lopansri, M.D. is uniquely suited to speak on the impact of the changing landscapes of healthcare and the value of flexible testing from both the clinician’s and laboratorian’s perspective, serving as the Chief of Infectious Diseases and Medical Director of the Urban Central Regional Microbiology Lab at Intermountain Health.
A new Q&A with Dr. Lopansri is now available that discusses:
- A clinician’s thought process when evaluating a patient that presents with a possible respiratory tract infection
- The consciousness of clinicians about out-of-pocket payment for their patients
- The value clinicians see in flexible testing for respiratory pathogens and other disease states
“Just because we are capable of detecting most of the major respiratory pathogens in a single test doesn’t mean that we need to be doing so routinely,” says Dr. Lopansri in the Q+A. “Be prepared to address the physician who only wants to look for influenza and doesn’t need to know about rhinovirus or coronavirus, since there isn’t much you can do beyond supportive care anyway.”
Click here to download the full Q&A with Dr. Lopansri.